Alzheimer therapy with an antibody against N-terminal Abeta 4-X and pyroglutamate Abeta 3-X

Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer’s disease

(2014) Thomas A. Bayer et al.   ACTA NEUROPATHOLOGICA

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

(2014) Stephen Salloway et al.   NEW ENGLAND JOURNAL OF MEDICINE

N-truncated amyloid β (Aβ) 4-42 forms stable aggregates and induces acute and long-lasting behavioral deficits

(2013) Yvonne Bouter et al.   ACTA NEUROPATHOLOGICA

Pyroglutamate-3 Amyloid-β Deposition in the Brains of Humans, Non-Human Primates, Canines, and Alzheimer Disease–Like Transgenic Mouse Models

(2013) Jeffrey L. Frost et al.   AMERICAN JOURNAL OF PATHOLOGY

Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation

(2013) Luke A. Miles et al.   Scientific Reports

N-truncated Abeta starting with position four: early intraneuronal accumulation and rescue of toxicity using NT4X-167, a novel monoclonal antibody

(2013) Gregory Antonios et al.   Acta Neuropathologica Communications

Pyroglutamate Amyloid β (Aβ) Aggravates Behavioral Deficits in Transgenic Amyloid Mouse Model for Alzheimer Disease

(2012) Jessica L. Wittnam et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes

(2012) Iryna Benilova et al.   NATURE NEUROSCIENCE

Passive Immunization against Pyroglutamate-3 Amyloid-ß Reduces Plaque Burden in Alzheimer-Like Transgenic Mice: A Pilot Study

(2012) Jeffrey L. Frost et al.   Neurodegenerative Diseases

A Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice

(2012) Ronald B. DeMattos et al.   NEURON

Aβ Oligomer-Induced Synapse Degeneration in Alzheimer’s Disease

(2011) Kyle C. Wilcox et al.   CELLULAR AND MOLECULAR NEUROBIOLOGY

Pyroglutamate Amyloid-β (Aβ): A Hatchet Man in Alzheimer Disease

(2011) Sadim Jawhar et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

‘Clinical trials in Alzheimer’s disease’: immunotherapy approaches

(2011) Julien Delrieu et al.   JOURNAL OF NEUROCHEMISTRY

Robust Amyloid Clearance in a Mouse Model of Alzheimer's Disease Provides Novel Insights into the Mechanism of Amyloid-  Immunotherapy

(2011) A. Wang et al.   JOURNAL OF NEUROSCIENCE

Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer’s disease

(2010) Erik Portelius et al.   ACTA NEUROPATHOLOGICA

Presenilin-1 but not amyloid precursor protein mutations present in mouse models of Alzheimer’s disease attenuate the response of cultured cells to γ-secretase modulators regardless of their potency and structure

(2010) Stefanie Hahn et al.   JOURNAL OF NEUROCHEMISTRY

Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Aβ aggregation in the 5XFAD mouse model of Alzheimer's disease

(2010) Sadim Jawhar et al.   NEUROBIOLOGY OF AGING

Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer’s disease cases

(2009) Oliver Wirths et al.   JOURNAL OF NEURAL TRANSMISSION

A  Immunotherapy: Intracerebral Sequestration of A  by an Anti-A  Monoclonal Antibody 266 with High Affinity to Soluble A 

(2009) K. Yamada et al.   JOURNAL OF NEUROSCIENCE

Glutaminyl cyclase inhibition attenuates pyroglutamate Aβ and Alzheimer's disease–like pathology

(2008) Stephan Schilling et al.   NATURE MEDICINE

N-truncated amyloid-β oligomers induce learning impairment and neuronal apoptosis

(2007) Ihsen Youssef et al.   NEUROBIOLOGY OF AGING